McWilliams Lorna, Groves Samantha, Howell Sacha J, French David P
Division of Psychology and Mental Health, School of Health Sciences, Manchester Center for Health Psychology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
NIHR Manchester Biomedical Research Center, Manchester Academic Health Science Center, Manchester University NHS Foundation Trust, Manchester, England.
Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1275-1283. doi: 10.1158/1055-9965.EPI-21-1386.
Individuals with morbidity experience worse breast cancer outcomes compared with those without. This meta-analysis assessed the impact of morbidity on breast cancer-screening attendance and subsequent early detection (PROSPERO pre-registration CRD42020204918). MEDLINE, PsychInfo, and CINAHL were searched. Included articles published from 1988 measured organized breast-screening mammography attendance using medical records by women with morbidity compared with those without. Morbidities were assigned to nine diagnostic clusters. Data were pooled using random-effects inverse meta-analyses to produce odds ratios (OR) for attendance. 25 study samples (28 articles) were included. Data were available from 17,755,075 individuals, including at least 1,408,246 participants with one or more conditions;16,250,556 had none. Individuals with any morbidity had lower odds of attending breast screening compared with controls [k = 25; OR, 0.76; 95% confidence interval (CI), 0.70-0.81; P = <0.001; I2 = 99%]. Six morbidity clusters had lower odds of attendance. The lowest were for neurological, psychiatric, and disability conditions; ORs ranged from 0.45 to 0.59 compared with those without. Morbidity presents a clear barrier for breast-screening attendance, exacerbating health inequalities and, includes a larger number of conditions than previously identified. Consensus is required to determine a standardized approach on how best to identify those with morbidity and determine solutions for overcoming barriers to screening participation based on specific morbidity profiles.
与无疾病的个体相比,患有疾病的个体乳腺癌预后更差。本荟萃分析评估了疾病对乳腺癌筛查参与率及后续早期发现的影响(PROSPERO预注册编号CRD42020204918)。检索了MEDLINE、PsychInfo和CINAHL数据库。纳入的文章发表于1988年以后,比较了患有疾病和无疾病的女性使用医疗记录进行有组织的乳腺筛查钼靶检查的情况。疾病被分为9个诊断类别。使用随机效应逆荟萃分析汇总数据,以得出参与筛查的比值比(OR)。纳入了25个研究样本(28篇文章)。数据来自17755075名个体,其中至少1408246名参与者有一种或多种疾病;16250556名无疾病。与对照组相比,患有任何疾病的个体参加乳腺筛查的几率更低[k = 25;OR,0.76;95%置信区间(CI),0.70 - 0.81;P = <0.001;I2 = 99%]。6个疾病类别参加筛查的几率较低。最低的是神经、精神和残疾类疾病;与无疾病者相比,OR范围为0.45至0.59。疾病对乳腺筛查参与构成了明显障碍,加剧了健康不平等,且涉及的疾病种类比之前确定的更多。需要达成共识,以确定一种标准化方法,来最佳地识别患有疾病的个体,并根据特定疾病概况确定克服筛查参与障碍的解决方案。